ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,241 to 3,260 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Hospitalization556 of 1,108

605 of 1,096

-5.0 points

-9.2 to -0.9

2,204NCT00911508

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Left Atrial Ablation vs Rate or Rhythm Control Therapy: deaths from any cause58 of 1,108

67 of 1,096

-0.9 points

-2.8 to 1.1

2,204NCT00911508

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Death or Disabling Stroke24 of 1,108

27 of 1,096

-0.3 points

-1.6 to 1.0

2,204NCT00911508

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

Left Atrial Ablation vs Rate or Rhythm Control Therapy: serious adverse events454 of 1,108

430 of 1,096

1.7 points

-2.3 to 5.8

2,204NCT00911508

Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial

On Pump vs Off Pump: Short-term End Point61 of 1,099

77 of 1,104

-1.4 points

-3.5 to 0.6

2,203NCT00032630

Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass

On Pump vs Off Pump: serious adverse events201 of 1,099

220 of 1,104

-1.6 points

-4.9 to 1.6

2,203NCT00032630

Outcomes Following Myocardial Revascularization: On and Off Cardiopulmonary Bypass

On-Pump vs Off-Pump: deaths from any cause131 of 1,099

168 of 1,104

-3.3 points

-6.2 to -0.4

2,203NCT01924442

ROOBY Trial Follow-up Extension

On-Pump vs Off-Pump: serious adverse events426 of 1,099

496 of 1,104

-6.2 points

-10.3 to -2.0

2,203NCT01924442

ROOBY Trial Follow-up Extension

Percutaneous Coronary Intervention Group vs Medical Therapy Group: Number of Patients That Had a First Occurrence of the Primary End Point (Composite of Death From Any Cause, Nonfatal MI, or Class IV HF)230 of 1,101

219 of 1,100

1.0 points

-2.4 to 4.3

2,201NCT00004562

Occluded Artery Trial (OAT)

Percutaneous Coronary Intervention Group vs Medical Therapy Group: serious adverse events226 of 1,101

227 of 1,100

-0.1 points

-3.5 to 3.3

2,201NCT00004562

Occluded Artery Trial (OAT)

Pharmacist Intervention vs Control - Usual Care: Number of Participants With PTH Measurement During the Study Period502 of 1,070

182 of 1,129

30.8 points

27.1 to 34.4

2,199NCT01290614

A Chronic Care Model Based Quality Improvement (QI) Program to Improve the Care of Patients With Chronic Kidney Disease (CKD)

Chemotherapy vs Atezolizumab and Chemotherapy: deaths from any cause58 of 1,098

72 of 1,101

-1.3 points

-3.3 to 0.7

2,199NCT03498716

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

Intervention vs Control: Prevalence of Hypothermia at 24 Hours Post-randomisation448 of 1,096

585 of 1,101

-12.3 points

-16.4 to -8.1

2,197NCT02811432

Kangaroo Mother Care Before Stabilisation Amongst Low Birth Weight Neonates in Africa

Intervention Arm vs Control Arm: Patient Survival- Percentage of Patients That Died During Study195 of 1,300

144 of 896

-1.1 points

-4.2 to 2.0

2,196NCT03860818

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Intervention Arm vs Control Arm: Number of Participants With Graft Survival1,255 of 1,300

864 of 896

0.1 points

-1.4 to 1.8

2,196NCT03860818

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Intervention Arm vs Control Arm: deaths from any cause195 of 1,300

144 of 896

-1.1 points

-4.2 to 2.0

2,196NCT03860818

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Intervention Arm vs Control Arm: serious adverse events436 of 1,300

412 of 896

-12.4 points

-16.6 to -8.3

2,196NCT03860818

Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Nirsevimab vs No Intervention: Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants)7 of 1,132

2 of 1,062

0.4 points

-0.2 to 1.1

2,194NCT05437510

Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

Bivalirudin vs Standard of Care: Heparins With Optional GPI: serious adverse events145 of 1,099

129 of 1,094

1.4 points

-1.4 to 4.2

2,193NCT01087723

European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial

Group 1: Ad26.Mos.HIV Vaccine vs Group 2: Placebo: Number of Participants With Human Immuno Deficiency Virus-1 (HIV-1) Infection Diagnosed Between Month 7 to Month 24 Post Enrollment54 of 1,080

65 of 1,108

-0.9 points

-2.8 to 1.1

2,188NCT03060629

A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=163"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=163

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00911508-cf0db215",
        "title": "Left Atrial Ablation vs Rate or Rhythm Control Therapy: Number of Participants With Cardiovascular Hospitalization",
        "summary": "556 of 1108 against 605 of 1096; risk difference -5.0 points, 95% interval -9.2 to -0.9; NCT00911508, Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial",
        "record": "/library/comparisons/NCT00911508-cf0db215",
        "nct_id": "NCT00911508",
        "kind": "outcome",
        "participants": 2204,
        "risk_difference": {
          "value": -0.050202245118448396,
          "lower": -0.09164186705801602,
          "upper": -0.008514553663830783
        },
        "group_1": "556 of 1,108",
        "group_2": "605 of 1,096",
        "difference": "-5.0 points",
        "interval": "-9.2 to -0.9",
        "trial_title": "Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial"
      },
      {
        "id": "NCT00911508-deaths",
        "title": "Left Atrial Ablation vs Rate or Rhythm Control Therapy: deaths from any cause",
        "summary": "58 of 1108 against 67 of 1096; risk difference -0.9 points, 95% interval -2.8 to 1.1; NCT00911508, Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial",
        "record": "/library/comparisons/NCT00911508-deaths",
        "nct_id": "NCT00911508",
        "kind": "deaths",
        "participants": 2204,
        "risk_difference": {
          "value": -0.008784816464201955,
          "lower": -0.028386354506702044,
          "upper": 0.010669185835948884
        },
        "group_1": "58 of 1,108",
        "group_2": "67 of 1,096",
        "difference": "-0.9 points",
        "interval": "-2.8 to 1.1",
        "trial_title": "Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=164",
  "request_id": "_L1vcw-pcWVtByL9"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?